Skip to main content
Metal-Based Drugs logoLink to Metal-Based Drugs
. 1998;5(4):197–206. doi: 10.1155/MBD.1998.197

Steric Determinants of Pt/DNA Interactions and Anticancer Activity

Trevor W Hambley 1,✉, Susan J Berners-Price 2, Murray S Davies 1, Connie I Diakos 1, Hui Meng Er 1, Ronald R Fenton 1, Edwina C H Ling 1, Evonne M Rezler 1
PMCID: PMC2365127  PMID: 18475844

Abstract

Studies directed at establishing the structural features that control Pt/DNA interactions and the anticancer activity of Pt drugs are described. [1H, 15N]-HSQC 2D NMR spectroscopic studies of the reactions of cisplatin with oligonucleotides containing ApG and GpA binding sites reveal dramatic differences in the rates of formation of monofunctional adducts at the two sites. When the reactant is cis-[Pt(NH3)2(OH2)2]2+ no such differences are observed suggesting that outer-sphere interactions between the reactant and the oligonucleotide may play a substantial role in determining the rates. Rates of closure to the bifunctional adducts are similar to those observed for cisplatin. Studies of the adduct profiles formed by sterically bulky and/or optically active complexes reveal that steric interactions play a major role in mediating the binding of Pt(ll) to DNA but that hydrogen bonds play less of a role. In vitro cytotoxic activities for these complexes do not always follow the trends that would be expected on the basis of the adduct profiles.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).


Articles from Metal-Based Drugs are provided here courtesy of Wiley

RESOURCES